HRP20240115T1 - Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom - Google Patents
Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom Download PDFInfo
- Publication number
- HRP20240115T1 HRP20240115T1 HRP20240115TT HRP20240115T HRP20240115T1 HR P20240115 T1 HRP20240115 T1 HR P20240115T1 HR P20240115T T HRP20240115T T HR P20240115TT HR P20240115 T HRP20240115 T HR P20240115T HR P20240115 T1 HRP20240115 T1 HR P20240115T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- bupropion
- use according
- Prior art date
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title claims 17
- 229960003086 naltrexone Drugs 0.000 title claims 17
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 28
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 14
- 229960001058 bupropion Drugs 0.000 claims 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 235000012054 meals Nutrition 0.000 claims 7
- 235000013305 food Nutrition 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000013265 extended release Methods 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000016261 weight loss Diseases 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 206010056465 Food craving Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acoustics & Sound (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Farmaceutski pripravak za uporabu u terapiji, naznačen time, da sadrži formulaciju s produljenim otpuštanjem naltreksona ili njegove farmaceutski prihvatljive soli i formulaciju s produljenim otpuštanjem bupropiona ili njegove farmaceutski prihvatljive soli, pri čemu se navedeni pripravak daje s hranom.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da se količina spomenutog bupropiona ili njegove farmaceutski prihvatljive soli nalazi u rasponu od oko 90 mg do oko 360 mg po danu, i količina naltreksona ili njegove farmaceutski prihvatljive soli nalazi se u rasponu od oko 4 mg do oko 32 mg po danu.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol sadrži nesekvestriranu formulaciju naltreksona ili njegove farmaceutski prihvatljive soli.
4. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da se spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol daje istovremeno s bupropionom ili njegovom farmaceutski prihvatljivom soli.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da se spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol daje prije od ili uzastopno nakon bupropiona ili njegove farmaceutski prihvatljive soli.
6. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da se spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol i spomenuti bupropion ili njegova farmaceutski prihvatljiva sol nalaze u pojedinačnom obliku za doziranje.
7. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da spomenuta hrana sadrži jelo s visokim udjelom masti.
8. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da spomenuta hrana sadrži obrok odabran iz skupine koju čine umjereno kaloričan, umjereno masan obrok od oko 575 kalorija i s procjenom masti od oko 23% od ukupnog kalorijskog sadržaja; visokokaloričan obrok s visokim sadržajem masti od oko 1000 kalorija i s procjenom masti od oko 50% od ukupnog kalorijskog sadržaja; i obrok koji potpada unutar raspona definiranog navedenim umjereno kaloričnim, umjereno masnim obrokom i navedenim visokokaloričnim obrokom s visokim sadržajem masti.
9. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da spomenuta hrana sadrži umjereno kaloričan, umjereno masan obrok.
10. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je plan liječenja za spomenuti naltrekson ili njegovu farmaceutski prihvatljivu sol i spomenuti bupropion ili njegovu farmaceutski prihvatljivu sol, kako slijedi:
oko 8 mg spomenutog naltreksona ili njegove farmaceutski prihvatljive soli i oko 90 mg spomenutog bupropiona ili njegove farmaceutski prihvatljive soli za prvi tjedan liječenja;
oko 16 mg spomenutog naltreksona ili njegove farmaceutski prihvatljive soli i oko 180 mg spomenutog bupropiona ili njegove farmaceutski prihvatljive soli za drugi tjedan liječenja;
oko 24 mg spomenutog naltreksona ili njegove farmaceutski prihvatljive soli i oko 270 mg spomenutog bupropiona ili njegove farmaceutski prihvatljive soli za treći tjedan liječenja; i
oko 32 mg spomenutog naltreksona ili njegove farmaceutski prihvatljive soli i oko 360 mg spomenutog bupropiona ili njegove farmaceutski prihvatljive soli za četvrti i bilo koji od naknadnih tjedana liječenja.
11. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol i spomenuti bupropion ili njegova farmaceutski prihvatljiva sol daju kao dvije tablete od 8 mg naltreksona s produljenim otpuštanjem dva puta dnevno i dvije tablete od 90 mg bupropiona s produljenim otpuštanjem dva puta dnevno.
12. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol i spomenuti bupropion ili njegova farmaceutski prihvatljiva sol daju u trajanju od najmanje 28 tjedana.
13. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se spomenuti naltrekson ili njegova farmaceutski prihvatljiva sol i spomenuti bupropion ili njegova farmaceutski prihvatljiva sol daju u trajanju od najmanje 56 tjedana.
14. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se pripravak koristi za utjecanje na gubljenje težine, smanjenje kardiovaskularnih rizičnih faktora, povećanje osjetljivosti na inzulin, smanjenje žudnje za hranom, liječenje stanja visceralne masnoće, olakšanje dobivanja na težini ili poticanje gubitka težine za vrijeme prestanka pušenja, i omogućavanje terapije za gubljenje težine kod pacijenata s teškom depresijom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41939510P | 2010-12-03 | 2010-12-03 | |
| EP21152314.7A EP3884947B1 (en) | 2010-12-03 | 2011-12-02 | Increasing drug bioavailability in naltrexone therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240115T1 true HRP20240115T1 (hr) | 2024-06-07 |
Family
ID=46172304
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240115TT HRP20240115T1 (hr) | 2010-12-03 | 2011-12-02 | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom |
| HRP20170734TT HRP20170734T1 (hr) | 2010-12-03 | 2017-05-16 | Povećana biodostupnost lijeka u terapiji naltreksonom |
| HRP20210618TT HRP20210618T1 (hr) | 2010-12-03 | 2021-04-19 | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170734TT HRP20170734T1 (hr) | 2010-12-03 | 2017-05-16 | Povećana biodostupnost lijeka u terapiji naltreksonom |
| HRP20210618TT HRP20210618T1 (hr) | 2010-12-03 | 2021-04-19 | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130245056A1 (hr) |
| EP (4) | EP2646031B9 (hr) |
| JP (5) | JP6008866B2 (hr) |
| KR (5) | KR102391511B1 (hr) |
| CN (1) | CN103313711A (hr) |
| AR (2) | AR093182A1 (hr) |
| AU (2) | AU2011336304B2 (hr) |
| BR (1) | BR112013013390A2 (hr) |
| CA (2) | CA3239386A1 (hr) |
| CL (1) | CL2013001564A1 (hr) |
| CY (2) | CY1118968T1 (hr) |
| DK (3) | DK2646031T3 (hr) |
| ES (2) | ES2625527T3 (hr) |
| FI (1) | FI3884947T3 (hr) |
| HR (3) | HRP20240115T1 (hr) |
| HU (3) | HUE034393T2 (hr) |
| IL (3) | IL226504B (hr) |
| LT (3) | LT2646031T (hr) |
| MX (1) | MX356801B (hr) |
| PL (3) | PL3884947T3 (hr) |
| PT (3) | PT3884947T (hr) |
| RS (3) | RS65198B1 (hr) |
| RU (1) | RU2640561C2 (hr) |
| SI (3) | SI3884947T1 (hr) |
| TW (1) | TWI618536B (hr) |
| WO (1) | WO2012075459A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316456B1 (en) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| MX356801B (es) * | 2010-12-03 | 2018-06-13 | Orexigen Therapeutics Inc | Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona. |
| AU2013271622B2 (en) | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
| US20180015042A1 (en) * | 2015-02-07 | 2018-01-18 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition for the treatment of obesity |
| JP2020515649A (ja) * | 2017-03-28 | 2020-05-28 | エルディーエヌ ファーマ リミテッド | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
| EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| EP1772147A2 (en) * | 2003-03-17 | 2007-04-11 | Japan Tobacco, Inc. | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| EP2316456B1 (en) * | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
| BRPI0613911A2 (pt) | 2005-07-27 | 2011-02-22 | Orexigen Therapeutics Inc | composições para afetar a perda de peso |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| AR058239A1 (es) | 2005-11-28 | 2008-01-23 | Orexigen Therapeutics Inc | Metodos para tratar trastornos de ansiedad |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| CA2655835C (en) * | 2006-06-19 | 2015-07-21 | Alpharma, Inc. | Abuse-resistant pharmaceutical compositions of opioid agonists |
| KR101264789B1 (ko) * | 2006-06-30 | 2013-05-15 | 엘지디스플레이 주식회사 | 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법 |
| CA2693992C (en) * | 2006-07-20 | 2017-01-31 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| KR101479324B1 (ko) | 2006-11-09 | 2015-01-05 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| DK2139485T3 (da) * | 2007-04-11 | 2013-01-21 | Biomarin Pharm Inc | Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| MX356801B (es) * | 2010-12-03 | 2018-06-13 | Orexigen Therapeutics Inc | Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona. |
-
2011
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active IP Right Grant
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 EP EP23209711.3A patent/EP4349369A3/en active Pending
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en active Application Filing
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active IP Right Grant
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active IP Right Grant
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Application Discontinuation
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Application Filing
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
-
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
-
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
-
2017
- 2017-05-16 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
-
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
-
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
-
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
-
2021
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
-
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
-
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240115T1 (hr) | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom | |
| JP2017506651A (ja) | 脂肪肝の低減または予防のための組成物および方法 | |
| JP6280535B2 (ja) | Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物 | |
| JP2015503593A5 (hr) | ||
| WO2008093848A1 (ja) | ホスファチジルコリンを含有する炎症マーカー低減組成物 | |
| JP2013544290A5 (hr) | ||
| EP3445358B1 (en) | Administration of dihydroberberine | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013516493A5 (hr) | ||
| JP2010138170A (ja) | 抗疲労組成物 | |
| TW200803865A (en) | Composition containing riboflavin and sesamins | |
| JP2020526485A5 (hr) | ||
| WO2011019735A3 (en) | Nutritional supplements | |
| RU2009145804A (ru) | Аксомадол для лечения боли от артроза | |
| RU2014146562A (ru) | Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий | |
| JP2017530142A5 (hr) | ||
| CN102283832B (zh) | 一种预防或治疗高血压肥胖患者的药物组合物及用途 | |
| JP2015507002A5 (hr) | ||
| JP2010090097A (ja) | 抗骨粗鬆症組成物 | |
| JP5734134B2 (ja) | 抗疲労用医薬組成物 | |
| WO2009108067A3 (en) | Fatty acid derivatives for use in the prevention and treatment of hsmi | |
| TWI604840B (zh) | Fat loss weight loss composition | |
| JP6143215B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| JP6281919B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| CN104540509A (zh) | 用于肝脏再生的药物组合物 |